[5-[2-(3,3-Dimethyl-2-oxobutoxy)-2-oxoethoxy]-4,4,5-trimethyl-3-oxohexan-2-yl] 2-[(2-methylpropan-2-yl)oxy]propanoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [5-[2-(3,3-Dimethyl-2-oxobutoxy)-2-oxoethoxy]-4,4,5-trimethyl-3-oxohexan-2-yl] 2-[(2-methylpropan-2-yl)oxy]propanoate
• 英文别名: [5-[2-(3,3-dimethyl-2-oxobutoxy)-2-oxoethoxy]-4,4,5-trimethyl-3-oxohexan-2-yl] 2-[(2-methylpropan-2-yl)oxy]propanoate
• 化学式: C₂₄H₄₂O₈
• 分子量: 458.6
• InChiKey: UCKIRNPJPWCDSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  32
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• US20140271780A1
  申请人：——

  公开号：US20140271780A1

  公开（公告）日：2014-09-18
• PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT
  申请人：Allergan, Inc.

  公开号：US20180161342A1

  公开（公告）日：2018-06-14

  Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
• IMPLANT FOR TREATMENT OF AN OCULAR CONDITION
  申请人：ENVISIA THERAPEUTICS, INC.

  公开号：US20180177718A1

  公开（公告）日：2018-06-28

  The present disclosure relates to the field of pharmaceutical compositions, ocular implants, and systems and methods for treating an ocular condition. In certain aspects, the disclosure provides ocular implant systems for treating post-operative inflammation. In certain aspects, the ocular implants taught herein are rapid release extended treatment implants.
• US9289413B2
  申请人：——

  公开号：US9289413B2

  公开（公告）日：2016-03-22